TipRanks on MSN

Exelixis and Merck advance LITESPARK-033: A new kidney cancer combo with high-stakes market potential

Exelixis ($EXEL) announced an update on their ongoing clinical study. Study Overview The LITESPARK-033 study, formally titled “A Phase 3, ...
Interesting Engineering

AlphaFold and the architecture that cracked protein structure

AlphaFold didn't accelerate biology by running faster experiments. It changed the engineering assumptions behind protein ...
BMJ Open

Critical time intervention for people leaving prison at risk of homelessness in England and Wales (PHaCT trial): a pilot feasibility randomised controlled trial

Objective To determine whether a full-scale randomised control trial (RCT) assessing the efficacy and cost-effectiveness of a ...
BMJ Open

High-dose intermittent theta burst stimulation targeting the individualised frontoparietal cognitive network for post-stroke cognitive impairment: protocol for a randomised ...

Introduction Cognitive impairment is a common consequence after stroke. Intermittent theta burst stimulation (iTBS) has emerged as a promising cognitive therapy. However, traditional iTBS typically ...